Azitra is trading at $0.82, down 8.80%; available reporting does not establish a cause for the decline.
- On October 29, Azitra announced it expanded ATR-04 trial eligibility to include rashes associated with KRAS and MEK inhibitors, and shortened certain washout periods.
- Broader market conditions are weak, but do not confirm a direct cause for Azitra’s move.